Intravenous immunoglobulin plus corticosteroid to prevent coronary artery abnormalities in Kawasaki disease: A meta-analysis

Heart

Volumn 99, Issue 2, 2013, Pages 76-82

  Chen, Shaojie ^a   Dong, Ying ^b   Yin, Yuehui ^a   Krucoff, Mitchell W ^c  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b CHILDREN S HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CORTICOSTEROID; DEXAMETHASONE; IMMUNOGLOBULIN; METHYLPREDNISOLONE; PREDNISOLONE;

CARDIOVASCULAR RISK; CHEMOPROPHYLAXIS; COMBINATION CHEMOTHERAPY; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG RESISTANCE; DRUG SAFETY; HIGH RISK PATIENT; HUMAN; INCIDENCE; META ANALYSIS; MONOTHERAPY; MUCOCUTANEOUS LYMPH NODE SYNDROME; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

CORONARY ARTERY DISEASE; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INCIDENCE; MUCOCUTANEOUS LYMPH NODE SYNDROME; WORLD HEALTH;

EID: 84871779394     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2012-302126     Document Type: Review

References (41)

1. Nakamura Y, Yanagawa H, Kawasaki T. Mortality among children with Kawasaki disease in Japan. N Engl J Med 1992;326:1246-9.
2. Holman RC, Curns AT, Belay ED, et al. Kawasaki syndrome hospitalizations in the United States, 1997 and 2000. Pediatrics 2003;112:495-501. (Pubitemid 37082095)
3. Kato H, Sugimura T, Akagi T, et al. Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study of 594 patients. Circulation 1996;94:1379-85. (Pubitemid 26307269)
4. Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease. Circulation 2004;110:2747-71.
5. Furusho K, Kamiya T, Nakano H, et al. High-dose intravenous gammaglobulin for Kawasaki disease. Lancet 1984;2:1055-8. (Pubitemid 15211522)
6. Murphy DJ Jr, Huhta JC. Treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 1987;316:881. (Pubitemid 17042012)
7. Newburger JW, Takahashi M, Beiser AS, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 1991;324:1633-9.
8. Nakamura Y, Yashiro M, Uehara R, et al. Epidemiologic features of Kawasaki disease inJapan: results ofthe 2007-2008 nationwide survey. J Epidemiol 2010;20:302-7.
9. Uehara R, Belay ED, Maddox RA, et al. Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan. Pediatr Infect Dis J 2008;27:155-60.
10. Kato H, Koike S, Yokoyama T. Kawasaki disease: effect of treatment on coronary artery involvement. Pediatrics 1979;63:175-9. (Pubitemid 9083134)
11. Millar K, Manlhiot C, Yeung RS, et al. Corticosteroid administration for patients with coronary artery aneurysms after Kawasaki disease may be associated with impaired regression. In J Cardiol 2012;154:9-13.
12. Jibiki T, Kato I, Shiohama T, et al. Intravenous immune globulin plus corticosteroids in refractory Kawasaki disease. Pediatr Int 2011;53:729-35.
13. Lang BA, Yeung RS, Oen KG, et al. Corticosteroid treatment of refractory Kawasaki disease. J Rheumatol 2006;33:803-9.
14. Wright DA, Newburger JW, Baker A, et al. Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroids. J Pediatr 1996;128:146-9. (Pubitemid 26028974)
15. Ogata S, Bando Y, Kimura S, et al. The strategy of immune globulin resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. J Cardiol 2009;53:15-19.
16. Miura M, Kohno K, Ohki H, et al. Effects of methylprednisolone pulse on cytokine levels in Kawasaki disease patients unresponsive to intravenous immunoglobulin. Eur J Pediatr 2008;167:1119-23.
17. Furukawa T, Kishiro M, Akimoto K, et al. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease. Arch Dis Child 2008;93:142-6. (Pubitemid 351204755)
18. Hashino K, Ishii M, Iemura M, et al. Retreatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. Pediatr Int 2001;43:211-17. (Pubitemid 32640933)
19. Shinohara M, Sone K, Tomomasa T, et al. Corticosteroids in the treatment of the acute phase of Kawasaki disease. J Pediatr 1999;135:465-9. (Pubitemid 30180475)
20. Sundel RP, Baker AL, Fulton DR, et al. Corticosteroids in the initial treatment of Kawasaki disease: report of a randomized trial. J Pediatr 2003;142:611-16. (Pubitemid 36737160)
21. Okada Y, Shinohara M, Kobayashi T, et al. Effect of corticosteroids in addition to intravenous gamma globulin therapy on serum cytokine levels in the acute phase of Kawasaki disease in children. J Pediatr 2003;143:363-7. (Pubitemid 37188322)
22. Jibiki T, Terai M, Kurosaki T, et al. Efficacy of intravenous immune globulin therapy combined with dexamethasone for the initial treatment of acute Kawasaki disease. Eur J Pediatr 2004;163:229-33. (Pubitemid 38657174)
23. Inoue Y, Okada Y, Shinohara M, et al. A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: clinical course and coronary artery outcome. J Pediatr 2006;149:336-41.
24. Newburger JW, Sleeper LA, McCrindle BW, et al. Randomized trial of pulse corticosteroid therapy for primary treatment of Kawasaki disease. N Engl J Med 2007;356:663-75.
25. Okada K, Hara J, Miki I, et al. Pulse methylprednisolone with gammaglobulin as an initial treatment for acute Kawasaki disease. Eur J Pediatr 2009;168:181-5.
26. Ogata S, Ogihara Y, Honda T, et al. Corticosteroid pulse combination therapy for refractory Kawasaki disease: a randomized trial. Pediatrics 2012;129:e17-23.
27. Kobayashi T, Saji T, Otani T, et al. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet 2012;379:1613-20.
28. Moher D, Libetati A, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analysis of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339:b2700.
29. Research Committee on Kawasaki Disease. Report of Subcommittee on Standardization of Diagnostic Criteria and Reporting of Coronary Artery Lesions in Kawasaki Disease. Tokyo: Ministry of Health and Welfare, 1984.
30. Ayusawa M, Sonobe T, Uemura S, et al. Revision of diagnostic guidelines for Kawasaki disease (the 5th revised edition). Pediatr Int 2005;47:232-4. (Pubitemid 40545436)
31. Wooditch AC, Aronoff SC. Effect of initial corticosteroid therapy on coronary artery aneurysm formation in Kawasaki disease: a meta-analysis of 862 children. Pediatrics 2005;116:989-95. (Pubitemid 44542830)
32. Yanagawa H, Yashiro M, Nakamura Y, et al. Epidemiologic pictures of Kawasaki disease in Japan: from the nationwide incidence survey in 1991 and 1992. Pediatrics 1995;95:475-9.
33. Kobayashi T, Inoue Y, Takeuchi K, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation 2006;113:2606-12. (Pubitemid 43948009)
34. Egami K, Muta H, Ishii M, et al. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. J Pediatr 2006;149:237-40. (Pubitemid 44128552)
35. Seki M, Kobayashi T, Kobayashi T, et al. External validation of a risk score to predict intravenous immunoglobulin resistance in patients with kawasaki disease. Pediatr Infect Dis J 2011;30:145-7.
36. de Zorzi A, Colan SD, Gauvreau K, et al. Coronary artery dimensions may be misclassified as normal in Kawasaki disease. J Pediatr 1998;133:254-8.
37. Suzuki A, Kamiya T, Arakaki Y, et al. Fate of coronary arterial aneurysms in Kawasaki disease. Am J Cardiol 1994;74:822-4. (Pubitemid 24312982)
38. Burns JC, Shike H, Gordon JB, et al. Sequelae of Kawasaki disease in adolescents and young adults. J Am Coll Cardiol 1996;28:253-7. (Pubitemid 26266648)
39. Mitani Y, Sawada H, Hayakawa H, et al. Elevated levels of high-sensitivity C-reactive protein and serum amyloid-A late after Kawasaki disease: association between inflammation and late coronary sequelae in Kawasaki disease. Circulation 2005;111:38-43. (Pubitemid 40070841)
40. Brown TJ, Crawford SE, Cornwall ML, et al. CD8 T lymphocytes and macrophages infiltrate coronary artery aneurysms in acute Kawasaki disease. J Infect Dis 2001;184:940-3. (Pubitemid 32881104)
41. Noto N, Okada T, Abe Y, et al. Characteristics of earlier atherosclerotic involvement in adolescent patients with Kawasaki disease and coronary artery lesions: significance of gray scale median on B-mode ultrasound. Atherosclerosis 2012;222:106-9.